research Hypertrichosis of the pinnae in a patient using panitumumab
Panitumumab can cause excessive ear hair growth.
Search
for
Sort by
Research
30 / 1000+ results research Abnormal hair growth in patients (pts) with metastatic colorectal cancer (mCRC) treated with the anti-epidermal growth factor receptor (EGFr) monoclonal antibody (mAb) panitumumab (Pmab)
Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.
research PRIDE syndrome associated with panitumumab treatment – case report and literature review
A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.
research Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
EGFR inhibitors can cause yellowish skin eruptions.
research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
research 128 Bimekizumab led to rapid & deep normalisation of molecular signatures associated with PASI sub-components, preceding clinical skin clearance
research Sacituzumab Govitecan-Hziy (Trodelvy™)
Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
research Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance
The new nanoparticles could improve melanoma treatment by working better than current options.
research A Single-Arm, Open-Label, Phase Ib Clinical Study Evaluating the Efficacy and Safety of Durvalumab in Combination with Albumin-Bound Paclitaxel and Carboplatin as Neoadjuvant Therapy for Resectable Stage III Non-Small Cell Lung Cancer
The treatment showed high response rates and was well-tolerated, potentially extending patient survival.
research Cutaneous adverse effects of targeted therapies
Targeted cancer therapies often cause serious skin problems that need careful management.
research Cetuximab-Associated Elongation of the Eyelashes
Cetuximab can cause eyelash growth, which is rare but manageable.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
research Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Dermatologic Reactions to Targeted Therapy
Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.
research PRIDE syndrome with lumbosacral hypertrichosis
EGFR inhibitors can cause unusual localized hair growth.
research Phase II trial of paclitaxel poliglumex (CT-2103) in pre- and post-menopausal women on hormonal replacement therapy (HRT) with non-small cell lung cancer (NSCLC).
Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)
Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Anticancer drugs in surface waters
Anticancer drugs are increasingly found in surface waters, and their long-term environmental effects are not well understood, requiring better testing methods.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Hair disorders in patients with cancer
Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
research Alopecia in patients treated with molecularly targeted anticancer therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research Pathogenesis and treatment options for chemotherapy‐induced alopecia: a systematic review
Scalp cooling is the most effective FDA-approved method to prevent chemotherapy-induced hair loss, but more research is needed for other treatments.
research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.